EU orphan designations
Every medicine the European Commission has designated as an orphan medicine for a rare disease, on the EMA's recommendation, with its current status.
Matching designations
2 matches| Substance | Intended use | Status | Designated |
|---|---|---|---|
| Brentuximab vedotin EU/3/11/939 20 clinical trials → |
Treatment of cutaneous T-cell lymphoma | Withdrawn | 11 Jan 2012 |
| monoclonal antibody against human CD30 covalently linked to the cytotoxin monomethylauristatin E (brentuximab vedotin) EU/3/08/596 · now authorised as Adcetris |
Treatment of Hodgkin's lymphoma | Withdrawn | 15 Jan 2009 |
How this page is built
Every row is copied from the EMA's orphan designations data, reproduced with acknowledgement of the source. Each substance links to its official EMA page.
- EMA orphan designations data (JSON report) ↗ active substance, intended use, EU designation number, date of designation, status and the link to each designation page
A daily job downloads the EMA's orphan designations JSON report and lists every designation, newest first. No AI drafting and no editorial pass. See our editorial standards. The the EMA data on this page was last retrieved on 12 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.